OUTCOME OF FILIPINO CHILDREN WITH LUPUS NEPHRITIS TREATED WITH A MODIFIED TREATMENT REGIMEN USING CYCLOPHOSPHAMIDE

MT Collante*, C Bernal. University of Santo Tomas Hospital, Department of Pediatrics-Section of Paediatric Rheumatology, Manila, Philippines

Background and Aims The current therapeutic strategy for childhood-onset lupus nephritis (LN) involves an induction phase, aiming to promote remission, and a maintenance phase to control disease and prevent relapses. Various regimens have been used worldwide, which differ in drug of choice and dosage, and duration of the induction and maintenance phases. This study evaluated treatment outcome and adverse event occurrence in Filipinos with childhood-onset LN.

Methods Medical records of patients diagnosed with childhood-onset LN who received an extended induction phase of 9 months followed by a maintenance phase of 5 quarterly pulses from year 2006 to 2014 at the University of Santo Tomas Hospital were reviewed.

Results Nineteen patients completed the modified regimen (94.7% female, mean age 11.2±3.7 years at lupus diagnosis, mean LN duration to completion of treatment 30.6±5.2 months). At 9 months, 47.4% (9/19) reached complete remission, and 52.6% (10/19) were in partial remission. After 9 monthly and 5 quarterly pulses, 94.7% (18/19) was with partial response at the end of treatment. One patient relapsed during the maintenance phase and was with partial response at the end of treatment. The random urine protein-creatinine ratio and disease activity were significantly improved in all 19 patients.

Treatment failure was not noted in any of the patients at the end of maintenance phase and at completion. Reported adverse events were gastrointestinal symptoms (100%), mild infections (94.7%), alopecia (89.5%), severe infections (10.5%), menstrual irregularities (33.3%), and hematologic disturbances (26.3%).

Conclusions A modified regimen of 9 monthly and 5 quarterly cyclophosphamide pulses may be an effective therapeutic option for childhood-onset LN.

SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID ANTIBODIES IN A CHILD WITH NOONAN SYNDROME

1A Gupta*, 1A Kumar, 2N Todurkar, 3D Suri, 4Panigrahi, 5Ahlusalia, 6Singh. 1PGIMER, Allergy Immunology Unit- Advanced Paediatrics Centre, Chandigarh, India; 2PGIMER, Advanced Paediatrics Centre, Chandigarh, India; 3PGIMER, Genetics and Metabolic Unit-Advanced Paediatrics Centre, Chandigarh, India; 4PGIMER, Department of Haematology, Chandigarh, India

Background and Aims Autoimmune dysfunction has been described in patients with Noonan Syndrome (NS). Till date, 9 patients with systemic lupus erythematosus (SLE) and NS have been reported. However, exact relationship between SLE and NS is not known.

Methods To describe the clinical presentation of a child with SLE and NS.

Results A 10-years-old boy presented with fever, gradually progressive dyspnoea, pain in bilateral elbow and knee joints for 8 months. His past and family history was normal. Weight and height were <-3 z-score for his age. He had a long face with relatively large ears, down slanting palpebral fissure and livedo reticularis over lower limbs. Grade III ejection systolic murmur was present at pulmonary area along with loud second heart sound. He had hyperronia with brisk deep tendon reflexes in bilateral lower limbs, bilateral ankle clonus and extensor plantar response.

Investigations revealed anaemia, thrombocytopenia, leucopenia, elevated acute phase reactants and aPTT prolongation. His antinuclear antibody was positive by indirect immunofluorescence (4+ homogenous), anti-double stranded deoxyribonucleic acid was elevated and direct coomb test and lupus anticoagulant were positive along with low serum complement 3 level. Echocardiography revealed mitral valve prolapse and mitral regurgitation. Magnetic resonance imaging of brain revealed chronic lacunar infarct in medial aspect of right thalamus.

A diagnosis of SLE, APLA and NS was made and treatment with oral prednisolone, hydroxychloroquine, acetyl salicylate and low molecular weight heparin was initiated.

Conclusions Autoimmune conditions including SLE are being increasingly described in patients with NS requiring close monitoring and long term follow up.

SOLUBLE CXCL16 IN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS

A Hassan. Tanta, Egypt

Background and Aims Systemic lupus erythematosus (SLE) is characterised by autoantibodies directed against self antigens, leading to inflammatory damage of many target organs. The inflammatory soluble chemokine CXC motif ligand 16 (sCXCL160) has been proposed as an important pathogenic mediator in inflammatory diseases, such as juvenileSLE.